Skip to Content
Merck
All Photos(1)

Documents

71663

Sigma-Aldrich

Sodium phosphate dibasic dodecahydrate

tested according to Ph. Eur.

Synonym(s):

Dinatrii phosphas dodecahydricus, sec-Sodium phosphate, Disodium hydrogen phosphate dodecahydrate, Disodium phosphate, di-Sodium hydrogen phosphate dodecahydrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
Na2HPO4 · 12H2O
CAS Number:
10039-32-4
Molecular Weight:
358.14
EC Number:
231-448-7
MDL number:
MFCD00149181
UNSPSC Code:
12161700
PubChem Substance ID:
329763414
NACRES:
NA.25

Agency

USP/NF
tested according to Ph. Eur.

Quality Level

200

Assay

98.5-102.5%

form

crystalline

solubility

water: ~35.8 g/L at 20 °C

SMILES string

O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O

InChI

1S/2Na.H3O4P.12H2O/c;;1-5(2,3)4;;;;;;;;;;;;/h;;(H3,1,2,3,4);12*1H2/q2*+1;;;;;;;;;;;;;/p-2

InChI key

DGLRDKLJZLEJCY-UHFFFAOYSA-L

Looking for similar products? Visit Product Comparison Guide

Application


  • The gelation behavior of thiolated citrus high-methoxyl pectin induced by sodium phosphate dibasic dodecahydrate.: This research explores how sodium phosphate dibasic dodecahydrate influences the gelation properties of thiolated citrus pectin, showcasing potential applications in food science and pharmaceuticals for controlled gelation processes (Chen J et al., 2022).

  • Use of cellulose nanofibril (CNF)/silver nanoparticles (AgNPs) composite in salt hydrate phase change material for efficient thermal energy storage.: Demonstrates the utility of sodium phosphate dibasic dodecahydrate in enhancing the performance of phase change materials, which are critical for energy storage systems, indicating its role in improving thermal energy storage efficiency (Shen Z et al., 2021).

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCJ9559
BCCJ7917
BCCH7207
BCCH0519
BCCG3530

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Matthew H Crouthamel et al.
Arteriosclerosis, thrombosis, and vascular biology, 33(11), 2625-2632 (2013-08-24)
Elevated serum phosphate has emerged as a major risk factor for vascular calcification. The sodium-dependent phosphate cotransporter, PiT-1, was previously shown to be required for phosphate-induced osteogenic differentiation and calcification of cultured human vascular smooth muscle cells (VSMCs), but its
Matthew R Weir et al.
Journal of clinical hypertension (Greenwich, Conn.), 16(12), 875-882 (2014-10-21)
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis- and intravascular volume reduction-related adverse events (AEs) were evaluated using pooled data from four placebo-controlled, phase 3 studies in patients with type 2
Luciano Candilio et al.
Heart (British Cardiac Society), 101(3), 185-192 (2014-09-26)
Remote ischaemic preconditioning (RIPC), using brief cycles of limb ischaemia/reperfusion, is a non-invasive, low-cost intervention that may reduce perioperative myocardial injury (PMI) in patients undergoing cardiac surgery. We investigated whether RIPC can also improve short-term clinical outcomes. One hundred and
George G S Sandor et al.
International journal of cardiology, 179, 470-475 (2014-12-04)
Patients with Marfan (MFS) and Loeys-Dietz (LDS) syndromes have been shown to have abnormal aortic biophysical properties. The purpose of this study was to compare the effects of 12-months of therapy with atenolol or losartan on vascular function in young
Karen Sliwa et al.
Heart (British Cardiac Society), 100(24), 1967-1974 (2014-09-18)
Lack of evidence-based data on the spectrum of cardiovascular disease (CVD) in pregnancy or in the postpartum period, as well as on maternal and fetal outcome, provides challenges for treating physicians, particularly in areas of low resources. The objectives of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service